
|Videos|September 29, 2016
New Checkpoint Inhibitors Under Investigation in CLL
Author(s)Nitin Jain, MD
Nitin Jain, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, discusses the checkpoint inhibitors under investigation in chronic lymphocytic leukemia (CLL).
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5


















